Cytokinetics announced that Myqorzo is now available for prescription in 5 mg, 10 mg, 15 mg and 20 mg tablets in the U.S. Myqorzo was recently approved by the U.S. Food and Drug Administration for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. "With Myqorzo now available in the U.S., we are delivering on our long-standing commitment to patients living with obstructive HCM and turning the page onto a new chapter as a commercial biopharmaceutical company," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "This product launch is the culmination of decades of rigorous science, clinical development, and commercial readiness preparations, reflecting our unwavering commitment to making a meaningful difference in the lives of patients. We are grateful to the healthcare professionals, patients and advocates across the HCM community whose insights and partnerships helped bring Myqorzo to this important milestone. With our REMS program now live, and our supply chain and specialty pharmacy distribution network fully operational, we are proud to make Myqorzo available as a new treatment option for patients with oHCM."
Wall Street analysts forecast CYTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYTK is 89.33 USD with a low forecast of 61.00 USD and a high forecast of 136.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
Wall Street analysts forecast CYTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYTK is 89.33 USD with a low forecast of 61.00 USD and a high forecast of 136.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
2 Hold
0 Sell
Strong Buy
Current: 64.010
Low
61.00
Averages
89.33
High
136.00
Current: 64.010
Low
61.00
Averages
89.33
High
136.00
Barclays
Hang Hu
Overweight
initiated
$87
2026-01-28
New
Reason
Barclays
Hang Hu
Price Target
$87
AI Analysis
2026-01-28
New
initiated
Overweight
Reason
Barclays analyst Hang Hu assumed coverage of Cytokinetics with an Overweight rating and $87 price target. The firm says that given a "differentiated" label with flexibility of titration, it continues to view Myqorzo as a preferred drug over Camzyos in obstructive hypertrophic cardiomyopathy.
B. Riley
B. Riley
Buy
maintain
$90 -> $108
2026-01-21
Reason
B. Riley
B. Riley
Price Target
$90 -> $108
2026-01-21
maintain
Buy
Reason
B. Riley raised the firm's price target on Cytokinetics to $108 from $90 and keeps a Buy rating on the shares. Recent Myqorzo launch metrics show strong early uptake, with over 50% new patient share among roughly 700 high-volume HCPs by YE26 and formulary parity achieved despite a modest wholesale acquisition cost premium to Camzyos, positioning the product to compete on Risk Evaluation and Mitigation Strategy differentiation rather than price, the analyst tells investors in a research note. Near-term focus is on the Phase 3 ACACIA Non-obstructive Hypertrophic Cardiomyopathy readout expected in early 2Q26, which could drive a halo effect in hypertrophic cardiomyopathy share capture, supported by a higher-dose, faster titration protocol and rigorous patient selection that improve on prior peer trial outcomes, the firm says.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CYTK
Unlock Now
Morgan Stanley
Maxwell Skor
Overweight
maintain
$71 -> $90
2026-01-08
Reason
Morgan Stanley
Maxwell Skor
Price Target
$71 -> $90
2026-01-08
maintain
Overweight
Reason
Morgan Stanley analyst Maxwell Skor raised the firm's price target on Cytokinetics to $90 from $71 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech's outperformance in 2026 as commercial names transition from "capital consumers to producers" and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
Leerink
Roanna Ruiz
Outperform
maintain
$73 -> $83
2025-12-22
Reason
Leerink
Roanna Ruiz
Price Target
$73 -> $83
2025-12-22
maintain
Outperform
Reason
Leerink analyst Roanna Ruiz raised the firm's price target on Cytokinetics to $83 from $73 and keeps an Outperform rating on the shares.
About CYTK
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
